Customize your JAMA Network experience by selecting one or more topics from the list below.
This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Investigators hope to complete clinical trials this month in Baltimore, Boston, and St Louis of a genetically engineered human protein for dissolving blood clots in coronary arteries and other vessels.
The substance is called tissue-type plasminogen activator, or t-PA (JAMA [MEDICAL NEWS] 1983; 250:2743-2744). Unlike other plasminogen activators such as streptokinase or urokinase, t-PA—which is found in only small amounts in the body—acts specifically on clots and not on other proteins in the blood.
The agent is being produced by Genentech Inc of South San Francisco, Calif, which focuses much of its efforts on developing products through recombinant DNA technology. The investigational trials, which are being conducted at the Johns Hopkins Hospital and City Hospitals in Baltimore, Massachusetts General Hospital in Boston, and Barnes Hospital of Washington University in St Louis, will involve up to 45 patients in all.
Persons who go to one of the participating hospitals shortly after
Gunby P. Clot-dissolving agent undergoes clinical trials. JAMA. 1984;251(13):1651–1652. doi:10.1001/jama.1984.03340370007003
Coronavirus Resource Center
Create a personal account or sign in to: